相似文献
1
Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia.
Crit Care. 2024 Jan 5;28(1):14. doi: 10.1186/s13054-023-04787-x.
2
Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
J Oncol Pharm Pract. 2018 Jan;24(1):67-73. doi: 10.1177/1078155216676633. Epub 2016 Oct 31.
3
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Cancer. 2021 Feb 15;127(4):554-559. doi: 10.1002/cncr.33298. Epub 2020 Nov 3.
4
Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia.
Am J Hematol. 2023 May;98(5):E113-E115. doi: 10.1002/ajh.26880. Epub 2023 Feb 24.
5
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Drug Des Devel Ther. 2016 Feb 18;10:757-65. doi: 10.2147/DDDT.S83848. eCollection 2016.
6
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Cancer. 2021 Apr 1;127(7):1039-1048. doi: 10.1002/cncr.33340. Epub 2020 Dec 1.
7
The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Nov;63(11):2754-2756. doi: 10.1080/10428194.2022.2090555. Epub 2022 Jun 21.
8
A review of blinatumomab, a novel immunotherapy.
J Oncol Pharm Pract. 2016 Aug;22(4):639-45. doi: 10.1177/1078155215618770. Epub 2015 Nov 24.
9
Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Hematology. 2022 Dec;27(1):917-927. doi: 10.1080/16078454.2022.2111992.
10
Bispecific antibodies in acute lymphoblastic leukemia therapy.
Expert Rev Hematol. 2020 Nov;13(11):1211-1233. doi: 10.1080/17474086.2020.1831380. Epub 2020 Nov 4.
引用本文的文献
1
[Modern immunotherapy and emergency situations : Toxicities of CAR T-cell therapies and BiTEs, their management, and their relevance in intensive care medicine].
Med Klin Intensivmed Notfmed. 2025 Sep 2. doi: 10.1007/s00063-025-01316-2.
2
Targeted antineoplastic therapy in critically ill cancer patients: a multicenter analysis of the iCHOP registry.
Ann Hematol. 2025 May 10. doi: 10.1007/s00277-025-06400-3.
3
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager.
J Immunother Cancer. 2025 Mar 13;13(3):e010063. doi: 10.1136/jitc-2024-010063.
4
Adverse events in the nervous system associated with blinatumomab: a real-world study.
BMC Med. 2025 Feb 6;23(1):72. doi: 10.1186/s12916-025-03913-6.
本文引用的文献
1
Critical illness in patients with hematologic malignancy: a population-based cohort study.
Intensive Care Med. 2021 Oct;47(10):1104-1114. doi: 10.1007/s00134-021-06502-2. Epub 2021 Sep 14.
2
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Lancet Haematol. 2021 May;8(5):e355-e364. doi: 10.1016/S2352-3026(21)00060-0.
3
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
4
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
Zotero 插件